

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Authors

Hayley Vandenboom,^{1*} Othman Akhtar,^{2*} Aniko Szabo,³ Ravi Narra,² Meera Mohan,² Anita D’Souza,² Marcelo Pasquini² and Binod Dhakal²

¹Department of Medicine; ²BMT and Cell Therapy, Division of Hematology/Oncology and ³Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA

**HV and OA contributed equally as first authors.*


Correspondence:
B. DHAKAL - bdhakal@mcw.edu

<https://doi.org/10.3324/haematol.2025.288174>

Received: May 15, 2025.
Accepted: August 4, 2025.
Early view: August 14, 2025.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary Online Content





Supplemental Figure 1: Study retrieval and identification for meta-analysis. Flow diagram displaying the process for study inclusion and exclusion in the systematic review and meta-analysis of CAR-T and BsAb following the PRISMA guidelines

Trials included in the sensitivity analysis

CAR-T: Frigault et. al; Lin et. al; Munshi et. al and Raje et. al

BsAb: Lekoshin et. al; van de Donk et. Al; Bumma 1 and 2 et. al





Supplemental Figure 2: Bar chart displaying the causes of death among the entire study cohort (A). Comparison of the causes of non-relapse deaths by CAR-T and BsAb (B).

Supplemental Table 1: Risk of bias of included studies using the methodological index for non-randomized studies (MINORS)

	Raje1 et al	Mailankody et al	Wang et al	Cowan et al	Asherlie et al	Cornell et al	Brudno et al	Lin et al	Raje2 et al	Munshi et al	Kumar et al	Frigault et al	Fu et al	Chen et al		Usmani et al	D'Souza et al	Vij et al	Bar et al	Madan et al	Bumma et al	Bahlis et al	Lesokhin et al	van de Donk et al
1. A clearly stated aim	2	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
2. Inclusion of consecutive patients	2	1	2	1	1	1	1	1	1	2	1	2	1	1	1	2	2	1	1	2	1	1	1	1
3. Prospective collection of data	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
4. Endpoints appropriate to the aim of the study	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
5. Unbiased assessment of the study endpoint	0	1	1	1	1	0	0	1	1	2	1	2	2	1	1	1	1	1	1	1	2	1	1	1
6. Follow-up period appropriate to the aim of the study	2	2	2	2	1	2	1	1	1	2	1	2	2	1	1	2	1	1	1	1	1	2	2	2
7. Loss of follow-up less than 5%	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2
8. Prospective calculation of the study size	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Item 9-12 only for comparative studies																								
9. Adequate control group																		0			0			
10. Contemporary groups																	2				2			
11. Baseline equivalence of groups																	1				1			
12. Adequate statistical analyses																	2				2			
TOTAL MINORS score	12	12	13	12	11	11	9	11	11	14	11	14	13	11	12	13	11	11	12	12	11	12	12	12
Maximum possible score	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	24	16	16	24	16	16	16

Legend	
Good quality	
Moderate quality	
Poor quality	

Trials included in the sensitivity analysis

CAR-T: Frigault et. al; Lin et. al; Munshi et. al and Raje et. al

BsAb: Lekoshin et. al; van de Donk et. Al; Bumma 1 and 2 et. al

References

1. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. May 2 2019;380(18):1726-1737. doi:10.1056/NEJMoa1817226
2. Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. *Nature Medicine*. 2023/02/01 2023;29(2):422-429. doi:10.1038/s41591-022-02182-7
3. Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. *Blood*. May 27 2021;137(21):2890-2901. doi:10.1182/blood.2020008936
4. Cowan AJ, Pont MJ, Sather BD, et al. γ -Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. *Lancet Oncol*. Jul 2023;24(7):811-822. doi:10.1016/s1470-2045(23)00246-2
5. Asherie N, Kfir-Erenfeld S, Avni B, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. *Haematologica*. Jul 1 2023;108(7):1827-1839. doi:10.3324/haematol.2022.281628
6. Cornell RF, Bishop MR, Kumar S, et al. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. *Am J Cancer Res*. 2021;11(6):3285-3293.
7. Brudno JN, Maric I, Hartman SD, et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. *J Clin Oncol*. Aug 1 2018;36(22):2267-2280. doi:10.1200/jco.2018.77.8084
8. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. *Journal of Clinical Oncology*. 2023/06/01 2023;41(16_suppl):8009-8009. doi:10.1200/JCO.2023.41.16_suppl.8009
9. Raje NS, Shah N, Jagannath S, et al. Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. *Blood*. 2021/11/23/ 2021;138:548. doi:<https://doi.org/10.1182/blood-2021-146518>
10. Munshi Nikhil C, Anderson Larry D, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*. 2021/02/24 2021;384(8):705-716. doi:10.1056/NEJMoa2024850
11. Kumar SK, Baz RC, Orlowski RZ, et al. Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. *Blood*. 2020/11/05/ 2020;136:28-29. doi:<https://doi.org/10.1182/blood-2020-139802>
12. Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. *Blood Advances*. 2023;7(5):768-777. doi:10.1182/bloodadvances.2022007210
13. Fu C, Chen W, Cai Z, et al. Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma. *Blood*. 2023;142(Supplement 1):4845-4845. doi:10.1182/blood-2023-184373
14. Chen W, Fu C, Fang B, et al. Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*. 2022;140(Supplement 1):4564-4565. doi:10.1182/blood-2022-168610
15. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen $\times$ CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a

- multicentre, open-label, single-arm, phase 1 study. *Lancet*. Aug 21 2021;398(10301):665-674. doi:10.1016/s0140-6736(21)01338-6
16. D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. *Journal of Clinical Oncology*. 2022/11/01 2022;40(31):3576-3586. doi:10.1200/JCO.22.01504
17. Vij R, Kumar SK, D'Souza A, et al. Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*. 2023/11/02/ 2023;142:3378. doi:<https://doi.org/10.1182/blood-2023-182388>
18. Bar N, Mateos MV, Ribas P, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. *Blood*. 2023/11/02/ 2023;142:2011. doi:<https://doi.org/10.1182/blood-2023-180013>
19. Madan S, Costello CL, Lipe B, et al. Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM). *Blood*. 2023/11/02/ 2023;142:1012. doi:<https://doi.org/10.1182/blood-2023-182345>
20. Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. Aug 1 2024;42(22):2702-2712. doi:10.1200/jco.24.01008
21. Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. *Nat Med*. Oct 2023;29(10):2570-2576. doi:10.1038/s41591-023-02589-w
22. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. *Nature Medicine*. 2023/09/01 2023;29(9):2259-2267. doi:10.1038/s41591-023-02528-9
23. van de Donk NWCJ, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). *Journal of Clinical Oncology*. 2023/06/01 2023;41(16_suppl):8011-8011. doi:10.1200/JCO.2023.41.16_suppl.8011